v3.26.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net loss $ (3,292,562) $ (2,670,705)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,897,679 2,455,796
Stock compensation 383,530 544,376
Bad debt expense 10,433 0
Gain on sale of real estate assets, net (150,099) (4,777,327)
Gain on disposition of assets and liabilities, net (3,416,501) 0
Impairment of goodwill and real estate assets 3,502,523 4,344,332
Amortization of financing costs 111,195 137,749
Amortization of below-market leases (2,487) (2,266)
Straight-line rent adjustment 5,100 (27,948)
Changes in operating assets and liabilities:    
Other assets (28,165) 36,322
Accounts payable and accrued liabilities 1,146,771 (411,908)
Deferred leasing costs (93,626) 14,052
Accrued real estate taxes (41,224) (839,159)
Net cash used in operating activities 24,839 (1,012,227)
Cash flows from investing activities:    
Real estate acquisitions 0 (9,444,465)
Additions to buildings and tenant improvements (459,117) (741,071)
Proceeds from sale of marketable securities 0 13,990
Proceeds from sales of real estate, net 8,749,479 21,544,343
Net cash provided by investing activities 8,290,362 11,372,797
Cash flows from financing activities:    
Proceeds from mortgage notes payable, net of issuance costs 0 6,592,396
Payment of debt issuance costs 0 (247,882)
Repayment of mortgage notes payable (9,270,409) (14,014,678)
Payment of deferred offering costs (49,652) 0
Distributions to noncontrolling interests (324,687) (433,804)
Net cash used in financing activities (9,834,968) (11,111,977)
Net decrease in cash equivalents and restricted cash (1,519,767) (751,407)
Cash, cash equivalents and restricted cash - beginning of period 7,422,359 8,036,496
Cash, cash equivalents and restricted cash - end of period 5,902,592 7,285,089
Supplemental disclosure of cash flow information:    
Income taxes paid 57,000 46,511
Non-cash investing activities:    
Paid building and tenant improvements from prior year (361,261) (207,847)
Paid deferred offering costs from prior year 6,589 0
Non-cash financing activities:    
Unpaid building and tenant improvements 281,404 176,307
Dividends payable - Series D Preferred Stock 0 190,393
Mortgage Notes [Member]    
Supplemental disclosure of cash flow information:    
Interest paid-mortgage notes payable 3,222,606 2,998,056
Common Class A [Member]    
Cash flows from financing activities:    
Repurchase of Series A Common Stock, at cost 0 (1,526,551)
Series D Preferred Stock [Member]    
Cash flows from financing activities:    
Repurchase of Series D Preferred Stock, at cost 0 (327,787)
Dividends paid to Series D Preferred Stockholders (190,220) (1,153,671)
Conduit Pharmaceuticals Inc [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Net (gain) loss in Conduit Pharmaceuticals fair value marketable securities $ (7,728) $ 184,459